Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial

(Abstracted from JAMA Pediatr 2024;178(6):540–547 Spinal muscular atrophy (SMA) is a genetic disorder characterized by progressive muscle weakness and atrophy, with the most severe cases leading to ventilator dependency or death within 2 years. Three new therapies have significantly improved outcomes, especially with early treatment.

Authors

Publication Details

Journal
Obstetrical & Gynecological Survey
Published
2024-12-01
DOI
https://doi.org/10.1097/01.ogx.0001096632.82255.e5
Citations
2
Primary Topic
Neurogenetic and Muscular Disorders Research
Type
article
Field-Weighted Citation Impact
0.88
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial

Ralf A. Husain, Matthias Baumann, Marina Flotats‐Bastardas, Ekkehard Wilichowski et al.
2 citations
Obstetrical & Gynecological Survey
Neurogenetic and Muscular Disorders Research
0.88
article

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial

Ralf A. Husain, Matthias Baumann, Marina Flotats‐Bastardas, Ekkehard Wilichowski, Maggie Christine Walter, Janbernd Kirschner, Annette Schwerin-Nagel, Astrid Eisenkölbl, Regina Trollmann, Sebahattin Çırak, Andreas Ziegler, Arpad von Moers, Gert Wiegand, Wolfgang Müller‐Felber, Johannes Friese, Tim Hagenacker, Gudrun Schreiber, Manuela Baumgärtner, Ulrike Schara‐Schmidt, Max Behrens, Sabine Illsinger, Michelle Pfaffenlehner, Jessika Johannsen, Andreas Hahn, Günther Bernert, Katharina Vill, Hanns Lochmüller, Nadja Kaiser, Brice Kauffmann, Susanne Goldbach, Heike Kölbel, Martin Fleger, Cornelia Köhler, Claudia Weiß, Kristina Probst-Schendzielorz, Astrid Pechmann, Mareike Schimmel, Oliver Schwartz, Christian Rauscher, Martin Smitka, Dieter Gläser
article en
2 citations

Abstract

(Abstracted from JAMA Pediatr 2024;178(6):540–547 Spinal muscular atrophy (SMA) is a genetic disorder characterized by progressive muscle weakness and atrophy, with the most severe cases leading to ventilator dependency or death within 2 years. Three new therapies have significantly improved outcomes, especially with early treatment.

Obstetrical & Gynecological SurveyVol. 79(12)
Openalex Percentile: Top 22%
Neurogenetic and Muscular Disorders Research
0.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.